

Exploring the potential for collaborative use of an app-based platform for n-of-1 trials among healthcare professionals that treat patients with insomnia

1 **Jason R. Bobe, MSIS^{1*}, Jessica K. De Freitas, BS², Benjamin S. Glicksberg, PhD^{2*}**

2 ¹Department of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY, NY,
3 USA

4 ²Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai,
5 NY, NY, USA

6 *** Correspondence:**

7 Corresponding Authors

8 jason.bobe@mssm.edu & benjamin.glicksberg@mssm.edu

9

10 **Keywords:** n-of-1₁, sleep₂, qualitative research₃, mHealth₄, RWE₅, crossover₆, electronic health
11 records₆, clinical informatics₇

12 **Abstract**

13 **Background:** N-of-1 trials are single patient, multiple crossover, comparative effectiveness
14 experiments. Despite their rating as “level 1” evidence, they are not routinely used in clinical
15 medicine to evaluate the effectiveness of treatments.

16 **Objective:** We explored the potential for implementing a mobile app-based n-of-1 trial platform for
17 collaborative use by clinicians and patients to support data-driven decisions around the treatment of
18 insomnia.

19 **Methods:** A survey assessing awareness and utilization of n-of-1 trials was administered to
20 healthcare professionals that frequently treat patients with insomnia at the Icahn School of Medicine
21 at Mount Sinai in New York City. 1M electronic health records were analyzed to evaluate evidence
22 for a comorbid relationship between insomnia and dementia or Alzheimer’s disease among a patient
23 population that may benefit from n-of-1 trials for the selection of optimal sleep treatments.

24 **Results:** A total of 45 healthcare professionals completed the survey and were included in the
25 analysis. We found that 64% of healthcare professionals surveyed had not heard of n-of-1 trials. After
26 a brief description of these methods, 75% of healthcare professionals reported that they are likely or
27 highly likely to use an app-based n-of-1 trial at least once in the next year if the service were free and
28 easy to offer to their patients.

29 **Conclusions:** An app-based n-of-1 trials platform might be a valuable tool for clinicians and patients
30 to identify the best treatments for insomnia. Educational interventions that raise awareness and
31 provide training are also likely necessary. The electronic health record (EHR) may help identify
32 eligible patients.

33 **1 Introduction**

34 Healthcare professionals routinely practice individualized care. They design treatment plans based on
35 unique patient characteristics and clinical presentation, consider various levels of evidence for
36 treatment efficacy, and help patients weigh the risks of side effects and other potential treatment
37 burdens and trade-offs. While there is widespread agreement that we should not expect most
38 treatments to work uniformly across most populations, the systematic evaluation of treatment effect
39 remains a challenge for healthcare professionals and patients [1]. Healthcare professionals who
40 practice "evidence-based medicine" generally use comparisons of means and proportions between
41 large groups of patients (e.g. from clinical trials), but are intuitively aware that there exists large
42 heterogeneity of effects for many disease processes and interventions.(possible references). N-of-1
43 trials create an opportunity in some contexts for healthcare professionals and patients to
44 individualized treatment selection in a more systematic way. They are designed to help both parties
45 make objective, data-driven treatment choices.

46 **1.1 What are n-of-1 trials?**

47 In clinical medicine, N-of-1 trials are used as a decision support tool to inform individualized
48 treatment selection [2]. The Oxford Centre for Evidence-Based Medicine ranks n-of-1 trials as "level
49 1" evidence for determining whether a treatment benefits a patient [3]. N-of-1 trials are also viewed
50 as a tool to enhance patient-centered care, insofar as the patient may be involved in the selection of
51 treatments to compare, the selection of outcomes to measure, and the selection of the treatment to
52 continue at the end of the trial [4]. Typically in an n-of-1 trial, a single patient completes a baseline
53 period without any treatments, then alternates between two treatments in a sequence (i.e. "multiple
54 crossover") [5,6]. Where feasible, treatments may be blinded or placebo-controlled. Outcomes are
55 measured during baseline and each treatment period. At the end of the trial, outcome measurements
56 for each treatment are compared and a treatment is selected. N-of-1 trials may also be deployed to
57 answer other common treatment investigations, such as whether to begin a treatment, proper dosing
58 [7], disease-related nutrition recommendations [8–10], assessing treatment response in people with
59 characteristics (e.g. rare genetic variants) not studied in randomized controlled trials of approved
60 medications [11–13], and deprescribing [14], among others.

61

62 To be sure, n-of-1 trials are not useful in every context. They work best in patients with chronic or
63 stable conditions. Non-curative treatments with rapid onset and rapid washout are ideal candidates
64 for n-of-1 trials, whereas treatments with cumulative effectiveness (e.g. some antidepressants) or
65 treatments that disrupt the nature of the underlying condition (e.g. surgery) are not. N-of-1 trials are
66 particularly relevant in contexts where evidence for treatment efficacy is weak or where treatment
67 effects are known to be heterogeneous across populations and among individuals [5].

68

69 **1.2 Chronic insomnia: a testbed for implementation of n-of-1 trials**

70 There are many therapeutic contexts where n-of-1 trials are able to serve unmet patient needs.
71 Chronic insomnia is a good target disorder because there is a high prevalence of affected individuals
72 in the general population and also across distinct clinical populations, including Alzheimer's disease
73 (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD), pregnancy, post-
74 treatment cancer patients, and many others.

75

76 N-of-1 trials have been implemented or are currently underway in several populations with insomnia.
77 Coxeter et al. reported the effectiveness of valerian versus placebo in 24 patients with chronic
78 insomnia [15]. Punja et al. have described a protocol to assess the effectiveness of melatonin in
79 children (ages 6-17) taking medications for ADHD [16]. Nikles et al. have described a protocol to
80 assess the effectiveness of melatonin in patients with PD [17].

81

82 Many patient populations have insomnia. It is one of the most common mental disorders [18].
83 Patients with insomnia have significant interest in finding the most effective treatment due to the
84 negative impact on quality-of-life for patients, family and caregivers [19,20]. Poor sleep may also
85 interact with recovery or progression of some diseases, including cardiovascular disease, depression,
86 diabetes, AD, among others [21–25]. Estimates of the prevalence of insomnia in the general
87 population vary in part due to the definition of insomnia used. The American Academy of Sleep
88 Medicine (AASM) estimates that 33-50% of adults experience symptoms of insomnia and 10-15% of
89 adults experience insomnia disorders that disrupt daily functioning [26].

90

91 The International Classification of Sleep Disorders, 3rd Edition (ICSD-3) includes seven categories
92 of sleep disorders, including insomnia. The category of insomnia has three sub-types: chronic
93 insomnia disorder, short-term insomnia disorder, and other insomnia disorder. The criteria for
94 diagnosing chronic insomnia specify that a person must report a problem with sleep initiation or
95 maintenance while having an adequate opportunity and environment to sleep. Symptoms must also
96 cause clinically significant functional distress during the daytime; be present for at least three nights
97 per week for at least three months. Chronic insomnia is likely a heterogeneous disorder [27]. Brain
98 imaging studies, for example, have not found consistent patterns across patients with chronic
99 insomnia [28].

100

101 There is limited efficacy data available for insomnia treatments in many patient populations, so
102 decisional conflict is common. The American Academy of Physicians recommends cognitive
103 behavioral therapy for insomnia (CBT-I) as the first line therapy in adults with chronic insomnia
104 [29]. In a systematic review of randomized controlled trials (RCTs) that compared CBT-I and
105 medications for the treatment of insomnia, evidence supports the notion that CBT-I is better than
106 medications in some contexts [30]. However, among patients that choose to pursue CBT-I, around
107 20-30% fail to respond [31]. Furthermore, many people do not choose CBT-I because of several
108 treatment-related burdens, including limited access to trained healthcare professionals, weekly
109 therapy appointments, and out-of-pocket costs [32,33]. There is widespread use of pharmacological

110 interventions and over-the-counter sleep aids. Around 20% of U.S. adults use prescribed or over-the-
111 counter (OTC) sleeping medications each month [34]. While commonly used, many OTC sleep
112 treatments have limited efficacy and safety data [35]. Furthermore, some sleep medications that are
113 commonly used in younger populations for sleep problems are, for example, potentially inappropriate
114 for use in older populations (e.g. hypnotics or Z drugs) [36].

115

116 For n-of-1 trials to be an effective tool for patients and healthcare professionals, the design of these
117 trials should incorporate the precise needs of the populations they intend to serve. Next, we describe
118 one patient population where chronic sleep disturbance is a salient issue: individuals at risk for AD
119 with chronic sleep problems.

120 **1.3 Alzheimer's and sleep disturbance**

121 AD is a critical public health concern with an estimated 131 million people worldwide predicted to
122 be affected by the year 2050 [37]. More than six million older Americans have AD [38,39] and the
123 annual incidence of the disease is estimated to rise to one million cases by 2050, which is more than
124 double the current incidence [40]. Research into possible preventive measures is an urgent need,
125 especially for people at risk due to family history or genetic predisposition. Primary prevention of
126 AD is currently seen as the most effective strategy at reducing the prevalence of AD over the next
127 several decades [39]. In recent years, sleep has been identified as a potential modifiable risk factor
128 for prevention or delay of AD [41].

129

130 The connection between poor sleep and negative outcomes among the elderly population has long
131 been established. In the 1990s, a prospective study of elderly people living in New York City found
132 that insomnia among males was the strongest predictor of mortality and placement in a nursing home,
133 exceeding many other factors analyzed, including age, income, health, and activities of daily living
134 (ADL) [42]. Another prospective study found that older women with sleep disturbance were more
135 likely to get dementia or mild cognitive impairment (MCI) [43,44].

136

137 In 2017, a meta-analysis of 27 observational studies found that poor sleep might explain around
138 ~15% of cases of cognitive impairment or AD [45]. They observed that people with sleep problems
139 had a 1.55, 1.65, and 3.78 times higher risk for AD, cognitive impairment, and preclinical AD than
140 individuals without sleep problems, respectively [45]. They also examined the relative risks related to
141 specific sleep problems, including short and long sleep duration (1.86), poor sleep quality (1.62),
142 circadian rhythm abnormality (1.38), and insomnia (1.38) [45].

143

144 The conventional wisdom is that changes in the brain due to AD causes sleep disturbance. Indeed, the
145 prevalence of sleep problems among patients with AD range from 25-50% [46]. Recent evidence
146 suggests causality might also work in the other direction: sleep disturbance as a risk factor for
147 developing AD [24,41,47,48]. Several recent studies provide evidence of a plausible mechanism:
148 increased amyloid- β production during periods of sleep deprivation. A single night of sleep
149 deprivation leads to elevated amyloid- β -42 (A β 42) in the cerebrospinal fluid of healthy middle-aged

150 men [49]. In a small, 3-arm, crossover RCT researchers found that sleep deprivation increased
151 overnight amyloid- β (-38, -40, -42) levels by 25–30%, while regular sleep or sedated sleep showed
152 no change in A β levels [50]. The connection between sleep disturbance and risk for AD remains
153 unproven and other plausible mechanisms have been proposed [51].

154

155 With the emerging evidence around the importance of sleep, people with a family history of
156 Alzheimer’s disease and those with genetic risk factors (e.g. APOE-e4) are likely to be motivated to
157 find the most effective interventions to address chronic sleep problems. Indeed, the REVEAL Study
158 observed healthy behavior change among patients that received genetic risk information for
159 Alzheimer’s disease, even in the absence of any proven approaches to prevention [52]. This group of
160 individuals are likely to meet many of the criteria identified by clinicians in qualitative interviews
161 about ideal patients for n-of-1 trials: “proactive, cognitively intact, reliable, motivated, and engaged
162 in a trusting physician–patient relationship” [53].

163 **1.4 Key questions for the current study**

164 The purpose of this study is to collect preliminary evidence to inform potential routes for the
165 implementation of an app-based n-of-1 trial platform, called the N1 app. While this platform may be
166 adapted to inform the optimal selection of treatments for a variety of disorders and wellness-related
167 goals, patients with insomnia have been identified as a potential population to target due to the
168 prevalence of the condition, limited evidence for efficacy of treatments across some patient
169 populations, the possibility to incorporate wearable devices for the passive collection of outcome
170 measures [54], among others.

171

172 In this study we aim to assess the familiarity and experience with n-of-1 trials in a sample of
173 healthcare workers that frequently care for patients with insomnia. Further, we examine the
174 characteristics of a hospital patient population that may stand to benefit from n-of-1 trials for the
175 selection of optimal sleep treatments. One hypothesis is that healthcare professionals are currently
176 familiar with, but do not regularly use n-of-1 trials. A second hypothesis is that data mining of
177 Electronic Health Records (EHR) in a hospital, health system, or health plan could be a viable route
178 for n-of-1 trial patient recruitment, which we explore through the assessment of the comorbidity
179 relationship between insomnia and dementia.

180 **2 METHODS**

181 **2.1 Survey**

182 **2.1.1 Instrument**

183 The Office for the Protection of Human Subjects at Mount Sinai approved a protocol to administer a
184 voluntary, anonymous survey to healthcare professionals. The exploratory, cross-sectional survey
185 administered has three sections (a) sociodemographics (b) experience and satisfaction with the
186 treatment of patients with insomnia and (c) awareness and utilization of n-of-1 trials (see Datasheet
187 S1). The survey was administered online through REDCap (Research Electronic Data Capture) hosted
188 by the Icahn School of Medicine at Mount Sinai [55].

189

190 **2.1.2 Sample and recruitment**

191 We chose to recruit a sample of clinicians and nurse practitioners through the Department of
192 Psychiatry due to the regularity with which these healthcare professionals treat patients with
193 insomnia. We sent messages through the department mailing list and advertised at bimonthly Grand
194 Rounds events during October and November of 2019.

195 **2.1.3 Statistical analysis**

196 We primarily use standard descriptive statistics to summarize the survey results. We further assessed
197 differences of participants awareness of n-of-1 using two-sided Chi-squared test for categorical
198 variables and a t-test for continuous variables. Using the same methods, we also assessed
199 associations for willingness to use a n-of-1 digital service, which we binarized due to low sample size
200 and imbalanced responses into “More likely” (consisting of “Strongly agree” and “Agree” responses)
201 and “Less likely” (consisting of “Neutral”, “Disagree”, and “Strongly disagree” responses).

202 **2.2 Electronic Health Records Analysis**

203 **2.2.1 Clinical Cohort**

204 We utilize clinical data from the EHRs of the Mount Sinai Hospital (MSH). MSH is an urban,
205 tertiary care hospital located on the Upper East Side of Manhattan in New York City. The clinical
206 data contained within the EHRs consists of structured data of patient information such as encounters,
207 disease diagnoses, lab test results, vital signs, medication prescriptions, and procedures among
208 others.

209 **2.2.2 Phenotyping process and cohort breakdown**

210 For the current study, we restrict our research cohort to individuals with at least one recorded clinical
211 feature, who were at least 70 years old, with a minimum of five years of medical history in our
212 system, and ICD codes for both insomnia and AD or dementia (See Datasheet S2), leaving 2632
213 unique patients for subsequent analyses (see Figure S1). This filtering procedure allowed for more
214 robust phenotyping by prioritizing individuals 65 and older that are more likely to be regular patients
215 in the MSH system (i.e., currently 70 years or older with at least five years of prior history and at
216 least one diagnostic code). Due to HIPAA requirements, the ages of patients within the research
217 cohort are right-censored at age 90. The mean age of the cohort is 84.3 ± 12.5 (std). The self-reported
218 sex breakdown of the cohort is 71.1% female, 28.8% male, and 0.04% not available. The self-
219 reported race breakdown of the cohort is: 50.8% Caucasian (White), 30.4% African American
220 (Black), 12.8% Other, 6.6% Unknown, and 2.7% Asian. The self-reported ethnicity breakdown of the
221 cohort is: 43.9% Hispanic/Latino, 25.5% non-Hispanic/Latino, and 31.9% Unknown.

222 **2.2.3 Enrichment analysis**

223 We used a chi-squared test to evaluate the relationship between insomnia and AD or dementia. Our
224 null hypothesis is that the diseases are independent and they have no significant comorbidity
225 relationship. Specifically, we tabulated the number of individuals that pass the above filtering criteria
226 that have both AD or dementia diagnosis and an insomnia diagnosis, compared to those with one or
227 the other, and to those with neither.

228 **2.3 Ethics approval**

229 This study has been approved by the Institutional Review Board at the Icahn School of Medicine at
230 Mount Sinai (IRB-18-00789 & IRB-19-02369)

231 3 RESULTS

232 3.1 Survey Results

233 3.1.1 Sample characteristics

234 A total of 66 participants consented to the survey, 49 participants completed the survey and the
235 responses from 45 participants were included in the analysis (see Figure S2). This sample of 45
236 healthcare professionals from a large, urban hospital are mostly practicing clinicians (88.9%),
237 affiliated with the Department of Psychiatry (88.9%), in their first or second decade of clinical
238 practice (64.4%), with a primary specialty of Psychiatry and Neurology (93.3%) (see Table 1).

239 **Table 1:** Sociodemographics of the sample of healthcare professionals surveyed

Category	Variable	n	%
Age (mean +/- SD)	48.4 +/- 16.5	45	100.0
Sex	Female	26	57.8
	Male	18	40.0
	Not reported	1	2.2
Race	Asian	3	6.7
	Black or African American	2	4.4
	White	34	75.6
	Multiple	3	6.7
	Unknown / Not reported	3	6.7
Ethnicity	Hispanic/Latino	3	6.7
	Not Hispanic/Latino	41	91
	Unknown/Not reported	1	2.2
Clinical degree(s)	MD	39	86.7
	NP	5	11.1
	MD/NP	1	2.2
Years of clinical practice	0-10	20	44.4
	11-20	9	20.0

	21-30	7	15.6
	31-40	5	11.1
	>40	3	6.7
	Not reported	1	2.2
Department(s)	Psychiatry	43	95.6
	Psychiatry and Anesthesiology	1	2.2
	Not reported	1	2.2
Primary Specialty	Psychiatry and Neurology	42	93.3
	Other	1	2.2
	Not reported	2	4.4
Total	-	45	100.0

240

241 3.1.2 Experience and satisfaction of sample with current treatments for patients with insomnia

242 Most healthcare professionals surveyed frequently see patients with insomnia in their clinical practice
 243 with 88.9% reporting daily or weekly encounters. A majority of participants also expressed their
 244 dissatisfaction with available treatment options for their patients with insomnia, with 55.6%
 245 disagreeing or strongly disagreeing with the statement: “I am satisfied with the available treatment
 246 options for my patients with insomnia.” Participants also perceived their patients as being dissatisfied
 247 with available treatment options, with 62.2% disagreeing or strongly disagreeing with the statement:
 248 “My patients are satisfied with available treatment options for insomnia” (see Table 2).

249 **Table 2.** Summary of survey results from a sample of healthcare professionals on their experience and satisfaction with current
 250 treatments for insomnia

Question	Response	n	%
How often do you see patients in your practice with insomnia?	Daily	17	37.8
	Weekly	23	51.1
	Monthly	3	6.7

	Quarterly	2	4.4
	Total	45	100.0
I am satisfied with the available treatment options for my patients with insomnia	Strongly agree	2	4.4
	Agree	7	15.6
	Neutral	11	24.4
	Disagree	21	46.7
	Strongly disagree	4	8.9
My patients are satisfied with available treatment options for insomnia.	Strongly agree	0	0.0
	Total	45	100.0
	Agree	8	17.8
	Neutral	9	20.0
	Disagree	24	53.3
	Strongly disagree	4	8.9
	Total	45	100.0
Have you ever heard of n-of-1 trials?	No	29	64.4
	Yes	16	35.6

	Total	45	100.0
How likely are you to use a free service that made it easy for you to offer n-of-1 trials to select patients in your practice with insomnia in order to make data-driven treatment choices at least once in the next year?	Highly likely	12	30.0
	Likely	18	45.0
	Neutral	6	15.0
	Unlikely	3	7.5
	Highly unlikely	1	2.5
Total		40	100.0

251

252 3.1.3 Awareness and use of n-of-1 trials

253 Most participants surveyed were unfamiliar with the concept of n-of-1 trials, with 64.4% reporting
 254 that they had never heard of them before. Following this survey question, participants were presented
 255 with a short description of n-of-1 trials that also included a screenshot of the N1 app, a smartphone
 256 based n-of-1 trial platform developed at the Icahn School of Medicine (see Data sheet S1) [56,57].
 257 They were asked to consider the scenario that “a free service [existed] that made it easy for you to
 258 offer n-of-1 trials to select patients in your practice with insomnia. The patient would conduct the
 259 mobile app-based trial at home. At the conclusion of the trial, the analyzed results would be available
 260 to you and the patient to review together.” Excluding 5 participants that did not respond to this
 261 question, 75% of participants (i.e. 30 of 40) reported that they were either “likely” or “highly likely”
 262 to “use a service like this to make data-driven treatment choices at least once in the next year.”

263

264 Of the 16 healthcare professionals that reported that they were aware of n-of-1 trials, 3 reported that
 265 they had previously used an n-of-1 trial in the treatment of their patients. For the remaining 11
 266 participants that were aware of n-of-1 trials, had never used them in their clinical practice, and
 267 reported a primary reason for the lack of adoption, 45.4% cited inadequate training in n-of-1 trial
 268 design.

269

270 We further assessed the relationship between various questionnaire features and having heard of n-of-
 271 1 trials (n=45). We found no significant relationship between having heard of n-of-1 trials and age (p

272 = 0.54 , $t = -0.61$), sex ($p = 0.09$, X-squared = 2.91), race ($p = 0.10$, X-squared = 7.92), ethnicity ($p =$
 273 0.75, X-squared = 0.58), clinical degree ($p = 0.84$, X-squared = 0.04; one individual with both
 274 degrees not included), number of years practiced ($p = 0.29$, X-squared = 5.02), frequency of seeing
 275 patients with insomnia ($p = 0.50$, X-squared = 2.36), satisfaction of current treatments for insomnia
 276 ($p = 0.23$, X-squared = 5.65), or perceived patient satisfaction of current treatments for insomnia ($p =$
 277 0.80, X-squared = 0.99).


278

279 We also assessed the relationship between various questionnaire features and willingness to use a n-
 280 of-1 digital service app ($n=40$; binarized response). We found no significant relationship between
 281 willingness to use a digital app service and age ($p = 0.22$, $t = -1.27$), sex ($p = 0.23$, X-squared = 1.45),
 282 race ($p = 0.54$, X-squared = 3.13), ethnicity ($p = 0.20$, X-squared = 3.26), clinical degree ($p = 0.81$, X-
 283 squared = 0.06; one individual with both degrees not included), number of years practiced ($p = 0.67$,
 284 X-squared = 2.36), frequency of seeing patients with insomnia ($p = 0.64$, X-squared = 1.68),
 285 satisfaction of current treatments for insomnia ($p = 0.21$, X-squared = 5.87), or perceived patient
 286 satisfaction of current treatments for insomnia ($p = 0.82$, X-squared = 0.93).

287 3.2 Electronic Health Records clinical comorbidity analysis

288 In the EHR analysis, our goal was to discern whether an enriched comorbidity relationship between
 289 AD or dementia and insomnia was present in the MSH patient population. We present the breakdown
 290 of patients by ICD code for each disease category in Figure 1 (A and B). We further visualize the
 291 distribution and frequency of ICD codes between both disease categories in Figure 1C.

292 **Figure 1:** The breakdown of patients by each ICD-9-CM and ICD-10-CM code of each category, specifically for A) Alzheimer’s
 293 disease or dementia and B) insomnia. Note that there might be patients that have more than one associated code. C) a scatter plot
 294 visualizing the distribution and frequency of patients by number of ICD codes of each disease category. Here, we display the number
 295 of ICD codes associated for each patient for insomnia codes on the y-axis and AD or dementia codes on the x-axis.



296

297

298 The null hypothesis was that the two diseases were independent from one another. We performed a
299 chi-square assessment for the rates of individuals that passed our eligibility criteria (see Figure 1) had
300 instances of both diseases compared to one or the other against a background of those with neither
301 (see Table 3). From this analysis, we obtained a chi-squared test statistic of 2978 which corresponds
302 to a statistically significant p-value of $< 2.2 \times 10^{-16}$. Odds ratio was used to quantify the strength of the
303 relationship between insomnia and Alzheimer's/dementia. We obtained a relative risk of 3.01 and an
304 odds ratio of 3.57, with a 95% confidence interval of 3.40-3.75.

305 **Table 3:** A contingency table tabulating the number of patients in the Mount Sinai Hospital Electronic Health Records that pass our
306 filtering criteria with Alzheimer's disease (AD) or dementia and insomnia.

	AD/Dementia	No AD/dementia
Insomnia	2514	8997
No insomnia	10724	137030

307

308 4 DISCUSSION

309 The N1 app aims to facilitate the design, administration, and analysis of n-of-1 trials [56–58].
310 Individuals with insomnia or other chronic sleep disturbance issues are a population that may benefit
311 from access to n-of-1 trials for data-driven treatment selection. While these multi-crossover,
312 comparative effectiveness trials have been in use for decades, awareness and adoption by healthcare
313 professionals continues to face challenges, as our survey further indicates. Yet, we are encouraged
314 that the healthcare professionals sampled did also report substantial receptivity to future use of app-
315 based n-of-1 trials to inform the treatment of patients with insomnia provided there were a service
316 that made such trials free and easy to implement. The lack of awareness of n-of-1 trials coupled with
317 receptivity to their use suggests that educational interventions may address at a current barrier to
318 wider utilization of n-of-1 trials.

319

320 Historically, several centers have been established to support the implementation of these trials for
321 local clinicians as a service [7,53,59]. One center currently operates at the University of Queensland
322 in Australia with a focus on sleep [60]. While these centers have documented many cases where
323 patients and clinicians were aided in the selection of treatments, the centers are often experiments
324 themselves that last as long as funding permits their operation, for example. For a time in the United
325 States, there was a Current Procedural Terminology (CPT) code for “personalized medicine tests”
326 that suggested a route to reimbursement for the effort required to design, administer and analyze an
327 n-of-1 trial [4]. Writing in 2008, Kravitz et al. suggested that one alternative to the model where n-of-
328 1 trials take root and gain traction primarily through academic clinical centers is the possibility that
329 they “cast off some of their academic trappings and focus on appealing to what patients want and
330 need” [4].

331

332 One of the major challenges with prospective studies, including n-of-1 trials, is cohort identification
333 and recruitment. A benefit of working within a health system is the possibility of accessing
334 retrospective patient data within the EHR. Of course, there are plenty of challenges of working with
335 such data (e.g., bias and missingness) but the EHR also offers countless opportunities for research
336 and a promising resource for patient engagement [61]. For instance, study recruitment via EHRs and
337 patient portals are an emerging trend for pragmatic trials [62]. In our EHR analysis, we found a
338 significant comorbidity enrichment between sleep disturbances, specifically insomnia, and AD or
339 dementia. This finding is encouraging as it replicates a previously established association and
340 reinforces the notion of using the EHR to aid in the construction of cohorts with specific features for
341 research and recruitment.

342

343 While healthcare practitioners take into consideration each patient's unique characteristics and strive
344 to use the most up-to-date information to make informed therapeutic recommendations, there will
345 always be some variability and uncertainty in outcomes. Leveraging n-of-1 trials as self-contained
346 experiments can quantify individual outcomes and can better optimize treatment selection in some
347 contexts. We believe growth in the adoption of n-of-1 trials will enhance the precision of treatment
348 selection for many individuals. App-based platforms offer the potential to reduce some barriers, but
349 other challenges still remain.

350

351 **5 Acknowledgments**

352 This study is funded by the Icahn School of Medicine at Mount Sinai and a generous gift from Julian
353 Salisbury. Thanks to Drs. Richard Kravitz MD (UC Davis) and Andrew Avins MD (Kaiser
354 Permanente) for providing feedback on the survey instrument and the manuscript, and also thanks to
355 Alex Charney MD PhD (Mount Sinai) for providing feedback on the survey instrument. The authors
356 declare that the research was conducted in the absence of any commercial or financial relationships
357 that could be construed as a potential conflict of interest.

358

359 **6 Author contributions**

360 All authors listed have made a substantial, direct and intellectual contribution to the work, and
361 approved it for publication.

362

363 **7 Data availability**

364 The survey and electronic health record datasets for this manuscript are not publicly available
365 because of privacy considerations of patients and clinical practitioners.

366

367 **8 References**

- 368 1. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the
369 ultimate strategy for individualizing medicine? *Per Med.* 2011;8: 161–173.
370 doi:10.2217/pme.11.7
- 371 2. Samuel J, Holder T, Molony D. N-of-1 Trials as a Decision Support Tool in Clinical Practice: A
372 Protocol for a Systematic Literature Review and Narrative Synthesis. *Healthcare (Basel).*
373 2019;7. doi:10.3390/healthcare7040136
- 374 3. OCEBM Levels of Evidence - CEBM. In: CEBM [Internet]. 1 May 2016 [cited 8 Oct 2019].
375 Available: <https://www.cebm.net/2016/05/ocebm-levels-of-evidence/>
- 376 4. Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What ever
377 happened to N-of-1 trials? Insiders' perspectives and a look to the future. *Milbank Q.* 2008;86:
378 533–555. doi:10.1111/j.1468-0009.2008.00533.x
- 379 5. Mitchell G, Nikles J, editors. *The Essential Guide to N-of-1 Trials in Health.* Springer; 2015.
380 Available: <https://www.springer.com/gp/book/9789401771993>
- 381 6. Kravitz RL, Duan N, eds, and the DEcIDE Methods Center N-of-1 Guidance Panel (Duan N,
382 Eslick I, Gabler NB, Kaplan HC, Kravitz RL, Larson EB, Pace WD, Schmid CH, Sim I, Vohra
383 S). *Design and Implementation of N-of-1 Trials: A User's Guide.* Rockville, MD: AHRQ; 2014
384 Jan. Report No.: Publication No. 13(14)-EHC122-EF. Available:
385 <https://effectivehealthcare.ahrq.gov/products/n-1-trials/research-2014-5>
- 386 7. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The n-of-1
387 randomized controlled trial: clinical usefulness. Our three-year experience. *Ann Intern Med.*
388 1990;112: 293–299. doi:10.7326/0003-4819-112-4-293
- 389 8. Kaplan HC, Opiari-Arrigan L, Schmid CH, Schuler CL, Saeed S, Braly KL, et al. Evaluating
390 the Comparative Effectiveness of Two Diets in Pediatric Inflammatory Bowel Disease: A Study
391 Protocol for a Series of N-of-1 Trials. *Healthcare (Basel).* 2019;7.
392 doi:10.3390/healthcare7040129
- 393 9. Liu L, Zhang Y, Wei J, Chen Z, Yu J. A Pilot Study of Amino Acids in Unresectable Non-
394 Small-Cell Lung Cancer Patients During Chemotherapy: A Randomized Serial N-of-1 Trials
395 Design. *Nutr Cancer.* 2019;71: 399–408. doi:10.1080/01635581.2018.1515962
- 396 10. Soldevila-Domenech N, Boronat A, Langohr K, de la Torre R. N-of-1 Clinical Trials in
397 Nutritional Interventions Directed at Improving Cognitive Function. *Front Nutr.* 2019;6: 110.
398 doi:10.3389/fnut.2019.00110
- 399 11. Magaret AS, Mayer-Hamblett N, VanDevanter D. Expanding access to CFTR modulators for
400 rare mutations: The utility of n-of-1 trials. *J Cyst Fibros.* 2019. doi:10.1016/j.jcf.2019.11.011
- 401 12. Nick JA, St Clair C, Jones MC, Lan L, Higgins M, VX12-770-113 Study Team. Ivacaftor in
402 cystic fibrosis with residual function: Lung function results from an N-of-1 study. *J Cyst Fibros.*
403 2019. doi:10.1016/j.jcf.2019.09.013
- 404 13. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical
405 research for rare disease: opportunities, challenges, and solutions. *Mol Genet Metab.* 2009;96:
406 20–26. doi:10.1016/j.ymgme.2008.10.003

- 407 14. Clough AJ, Hilmer SN, Naismith SL, Gnjdjic D. The Feasibility of Using N-Of-1 Trials to
408 Investigate Deprescribing in Older Adults with Dementia: A Pilot Study. *Healthcare (Basel)*.
409 2019;7. doi:10.3390/healthcare7040161
- 410 15. Coxeter PD, Schluter PJ, Eastwood HL, Nikles CJ, Glasziou PP. Valerian does not appear to
411 reduce symptoms for patients with chronic insomnia in general practice using a series of
412 randomised n-of-1 trials. *Complement Ther Med*. 2003;11: 215–222. doi:10.1016/s0965-
413 2299(03)00122-5
- 414 16. Punja S, Nikles CJ, Senior H, Mitchell G, Schmid CH, Heussler H, et al. Melatonin in Youth: N-
415 of-1 trials in a stimulant-treated ADHD Population (MYNAP): study protocol for a randomized
416 controlled trial. *Trials*. 2016;17: 375. doi:10.1186/s13063-016-1499-6
- 417 17. Nikles J, O’Sullivan JD, Mitchell GK, Smith SS, McGree JM, Senior H, et al. Protocol: Using
418 N-of-1 tests to identify responders to melatonin for sleep disturbance in Parkinson’s disease.
419 *Contemp Clin Trials Commun*. 2019;15: 100397. doi:10.1016/j.conctc.2019.100397
- 420 18. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and
421 burden of mental disorders and other disorders of the brain in Europe 2010. *Eur*
422 *Neuropsychopharmacol*. 2011;21: 655–679. doi:10.1016/j.euroneuro.2011.07.018
- 423 19. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. *Sleep Med Rev*.
424 2010;14: 69–82. doi:10.1016/j.smr.2009.07.004
- 425 20. Edelson J, Byrnes J, Mitchell G, Heussler H, Melaku M, Nikles J. Protocol for a Longitudinal
426 Study of Melatonin Therapy and Cost Effectiveness Analysis in Stimulant-Treated Children with
427 ADHD and Insomnia: An N-of-1 Trial. *Contemporary Clinical Trials Communications*. 2020;
428 100530. doi:10.1016/j.conctc.2020.100530
- 429 21. Jansen PR, Watanabe K, Stringer S, Skene N, Bryois J, Hammerschlag AR, et al. Genome-wide
430 analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways.
431 *Nat Genet*. 2019;51: 394–403. doi:10.1038/s41588-018-0333-3
- 432 22. Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia
433 as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. *J*
434 *Affect Disord*. 2011;135: 10–19. doi:10.1016/j.jad.2011.01.011
- 435 23. Lane JM, Jones SE, Dashti HS, Wood AR, Aragam KG, van Hees VT, et al. Biological and
436 clinical insights from genetics of insomnia symptoms. *Nat Genet*. 2019;51: 387–393.
437 doi:10.1038/s41588-019-0361-7
- 438 24. Ju Y-ES, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional
439 relationship. *Nat Rev Neurol*. 2014;10: 115–119. doi:10.1038/nrneuro.2013.269
- 440 25. Fan M, Sun D, Zhou T, Heianza Y, Lv J, Li L, et al. Sleep patterns, genetic susceptibility, and
441 incident cardiovascular disease: a prospective study of 385 292 UK biobank participants. *Eur*
442 *Heart J*. 2019. doi:10.1093/eurheartj/ehz849
- 443 26. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation
444 and management of chronic insomnia in adults. *J Clin Sleep Med*. 2008;4: 487–504. Available:
445 <https://aasm.org/resources/clinicalguidelines/040515.pdf>

- 446 27. Benjamins JS, Migliorati F, Dekker K, Wassing R, Moens S, Blanken TF, et al. Insomnia
447 heterogeneity: Characteristics to consider for data-driven multivariate subtyping. *Sleep Med*
448 *Rev.* 2017;36: 71–81. doi:10.1016/j.smrv.2016.10.005
- 449 28. Tahmasian M, Noori K, Samea F, Zarei M, Spiegelhalder K, Eickhoff SB, et al. A lack of
450 consistent brain alterations in insomnia disorder: An activation likelihood estimation meta-
451 analysis. *Sleep Med Rev.* 2018;42: 111–118. doi:10.1016/j.smrv.2018.07.004
- 452 29. Qaseem A, Kansagara D, Forcica MA, Cooke M, Denberg TD, Clinical Guidelines Committee
453 of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A
454 Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med.*
455 2016;165: 125–133. doi:10.7326/M15-2175
- 456 30. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive
457 behavioral therapy for insomnia: a systematic review. *BMC Fam Pract.* 2012;13: 40.
458 doi:10.1186/1471-2296-13-40
- 459 31. Morin CM. Cognitive-behavioral approaches to the treatment of insomnia. *J Clin Psychiatry.*
460 2004;65 Suppl 16: 33–40. Available: <https://www.ncbi.nlm.nih.gov/pubmed/15575803>
- 461 32. Koffel E, Bramoweth AD, Ulmer CS. Increasing access to and utilization of cognitive behavioral
462 therapy for insomnia (CBT-I): a narrative review. *J Gen Intern Med.* 2018;33: 955–962.
463 doi:10.1007/s11606-018-4390-1
- 464 33. Morin CM. Issues and challenges in implementing clinical practice guideline for the
465 management of chronic insomnia. *J Sleep Res.* 2017;26: 673–674. doi:10.1111/jsr.12639
- 466 34. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications
467 for insomnia: NHANES 1999-2010. *Sleep.* 2014;37: 343–349. doi:10.5665/sleep.3410
- 468 35. Meolie AL, Rosen C, Kristo D, Kohrman M, Gooneratne N, Aguiard RN, et al. Oral
469 nonprescription treatment for insomnia: an evaluation of products with limited evidence. *J Clin*
470 *Sleep Med.* 2005;1: 173–187. Available: <https://www.ncbi.nlm.nih.gov/pubmed/17561634>
- 471 36. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American
472 Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication
473 Use in Older Adults. *J Am Geriatr Soc.* 2019;67: 674–694. doi:10.1111/jgs.15767
- 474 37. Alzheimer’s Disease International. World Alzheimer Report 2016. 2016. Available:
475 <https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf>
- 476 38. Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. *Alzheimers Dement.*
477 2013;9: 208–245. doi:10.1016/j.jalz.2013.02.003
- 478 39. Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical
479 and clinical Alzheimer’s disease in the United States. *Alzheimers Dement.* 2018;14: 121–129.
480 doi:10.1016/j.jalz.2017.10.009
- 481 40. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the
482 United States projected to the years 2000 through 2050. *Alzheimer Dis Assoc Disord.* 2001;15:
483 169–173. Available: <https://www.ncbi.nlm.nih.gov/pubmed/11723367>

- 484 41. Cordone S, Annarumma L, Rossini PM, De Gennaro L. Sleep and β -Amyloid Deposition in
485 Alzheimer Disease: Insights on Mechanisms and Possible Innovative Treatments. *Front*
486 *Pharmacol.* 2019;10: 695. doi:10.3389/fphar.2019.00695
- 487 42. Pollak CP, Perlick D, Linsner JP, Wenston J, Hsieh F. Sleep problems in the community elderly
488 as predictors of death and nursing home placement. *J Community Health.* 1990;15: 123–135.
489 doi:10.1007/BF01321316
- 490 43. Tranah GJ, Blackwell T, Stone KL, Ancoli-Israel S, Paudel ML, Ensrud KE, et al. Circadian
491 activity rhythms and risk of incident dementia and mild cognitive impairment in older women.
492 *Ann Neurol.* 2011;70: 722–732. doi:10.1002/ana.22468
- 493 44. Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP, Ensrud KE, et al. Sleep-disordered
494 breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. *JAMA.*
495 2011;306: 613–619. doi:10.1001/jama.2011.1115
- 496 45. Bubu OM, Brannick M, Mortimer J, Umasabor-Bubu O, Sebastião YV, Wen Y, et al. Sleep,
497 Cognitive impairment, and Alzheimer’s disease: A Systematic Review and Meta-Analysis.
498 *Sleep.* 2017;40. doi:10.1093/sleep/zsw032
- 499 46. Moran M, Lynch CA, Walsh C, Coen R, Coakley D, Lawlor BA. Sleep disturbance in mild to
500 moderate Alzheimer’s disease. *Sleep Med.* 2005;6: 347–352. doi:10.1016/j.sleep.2004.12.005
- 501 47. Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, et al. Disruption of the sleep-
502 wake cycle and diurnal fluctuation of β -amyloid in mice with Alzheimer’s disease pathology. *Sci*
503 *Transl Med.* 2012;4: 150ra122. doi:10.1126/scitranslmed.3004291
- 504 48. Minakawa EN, Wada K, Nagai Y. Sleep Disturbance as a Potential Modifiable Risk Factor for
505 Alzheimer’s Disease. *Int J Mol Sci.* 2019;20. doi:10.3390/ijms20040803
- 506 49. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JAHR. Effect of 1 night of
507 total sleep deprivation on cerebrospinal fluid β -amyloid 42 in healthy middle-aged men: a
508 randomized clinical trial. *JAMA Neurol.* 2014;71: 971–977. doi:10.1001/jamaneurol.2014.1173
- 509 50. Lucey BP, Hicks TJ, McLeland JS, Toedebusch CD, Boyd J, Elbert DL, et al. Effect of sleep on
510 overnight cerebrospinal fluid amyloid β kinetics. *Ann Neurol.* 2018;83: 197–204.
511 doi:10.1002/ana.25117
- 512 51. Lyon L. Is an epidemic of sleeplessness increasing the incidence of Alzheimer’s disease? *Brain.*
513 2019;142: e30. doi:10.1093/brain/awz087
- 514 52. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes
515 after genetic risk assessment for Alzheimer disease: The REVEAL Study. *Alzheimer Dis Assoc*
516 *Disord.* 2008;22: 94–97. doi:10.1097/WAD.0b013e31815a9dcc
- 517 53. Kravitz RL, Paterniti DA, Hay MC, Subramanian S, Dean DE, Weisner T, et al. Marketing
518 therapeutic precision: Potential facilitators and barriers to adoption of n-of-1 trials. *Contemp*
519 *Clin Trials.* 2009;30: 436–445. doi:10.1016/j.cct.2009.04.001
- 520 54. Walch O, Huang Y, Forger D, Goldstein C. Sleep stage prediction with raw acceleration and
521 photoplethysmography heart rate data derived from a consumer wearable device. *Sleep.* 2019.

- 522 doi:10.1093/sleep/zsz180
- 523 55. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
524 capture (REDCap)--a metadata-driven methodology and workflow process for providing
525 translational research informatics support. *J Biomed Inform.* 2009;42: 377–381.
526 doi:10.1016/j.jbi.2008.08.010
- 527 56. Bobe JR, Buros J, Golden E, Johnson M, Jones M, Percha B, et al. Factors Associated With Trial
528 Completion and Adherence in App-Based N-of-1 Trials: Protocol for a Randomized Trial
529 Evaluating Study Duration, Notification Level, and Meaningful Engagement in the Brain Boost
530 Study. *JMIR Res Protoc.* 2020;9: e16362. doi:10.2196/16362
- 531 57. N1app.org. In: N1 app [Internet]. [cited 19 Jan 2020]. Available: <http://n1app.org>
- 532 58. Golden E, Johnson M, Jones M, Viglizzo R, Bobe J, Zimmerman N. Measuring the effects of
533 caffeine and L-theanine on cognitive performance: a protocol for self-directed, mobile n-of-1
534 studies. 2019. doi:10.31219/osf.io/scnx6
- 535 59. Larson EB, Ellsworth AJ, Oas J. Randomized clinical trials in single patients during a 2-year
536 period. *JAMA.* 1993;270: 2708–2712. doi:10.1001/jama.1993.03510220064035
- 537 60. N-of-1 trials and sleep research - Centre for Clinical Research - University of Queensland. [cited
538 20 Jan 2020]. Available: <https://clinical-research.centre.uq.edu.au/nikles-group>
- 539 61. Glicksberg BS, Johnson KW, Dudley JT. The next generation of precision medicine:
540 observational studies, electronic health records, biobanks and continuous monitoring. *Hum Mol*
541 *Genet.* 2018;27: R56–R62. doi:10.1093/hmg/ddy114
- 542 62. Pfaff E, Lee A, Bradford R, Pae J, Potter C, Blue P, et al. Recruiting for a pragmatic trial using
543 the electronic health record and patient portal: successes and lessons learned. *J Am Med Inform*
544 *Assoc.* 2019;26: 44–49. doi:10.1093/jamia/ocy138